Brief: Biophytis Announces Top Line Results Of Sara-Interest Phase 2 Study
02/08/2021 07:03
Aug 2 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS ANNOUNCES TOP LINE RESULTS OF SARA-INTEREST PHASE 2 STUDY WITH
SARCONEOS (BIO101) IN SARCOPENIA
* SARCONEOS (BIO101) AT HIGHEST DOSE (350 MG BID) SHOWED A CLINICALLY
MEANINGFUL
IMPROVEMENT IN 400-METER WALK TEST (400MWT), PRIMARY ENDPOINT OF STUDY
* SARCONEOS (BIO101) SHOWED A VERY GOOD SAFETY PROFILE AT DOSES OF 175 MG
BID AND
OF 350 MG BID WITH NO SERIOUS ADVERSE EVENTS (AE) RELATED TO PRODUCT
Source text for Eikon: ID:nGNX54h7xB
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon